TY  - JOUR
AU  - de-la-Rosa, David
AU  - Martinez-Garcia, Miguel-Angel
AU  - Olveira, Casilda
AU  - Giron, Rosa
AU  - Maiz, Luis
AU  - Prados, Concepcion
PY  - 2016
DO  - 10.1177/1479972316643698
UR  - https://hdl.handle.net/10668/24513
T2  - Chronic respiratory disease
AB  - Patients with bronchiectasis (BE) present exacerbations that increase with severity of the disease. We aimed to determine the annual cost of BE treatment according to its severity, determined by FACED score, as well as the parameters associated with...
LA  - en
PB  - Sage Publications
KW  - Pharmacoeconomics
KW  - Pseudomonas aeruginosa
KW  - Antibacterial agents
KW  - Bronchiectasis
KW  - Disease exacerbation
KW  - Inhalation drug administration
KW  - Bronchodilator Agents
KW  - Pseudomonas aeruginosa
KW  - Anti-Bacterial Agents
KW  - Forced Expiratory Volume
KW  - Spain
KW  - Bronchiectasis
KW  - Pulmonary Disease, Chronic Obstructive
TI  - Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.
TY  - research article
VL  - 13
ER  -